Company description

and Operating Results Recent Developments BioTissue Asset Acquisition On January 21, 2026, we expanded our portfolio through the purchase and licensing of certain assets from BioTissue Holdings Inc.’s (“BioTissue”) surgical and wound care business. Specifically, we purchased the Neox® and Clarix® trademarks as well as two patents relating to technologies focused on certain orthopedic therapies, which may support future expansion into other clinical applications for our products. We also acquired a national commercial infrastructure through the hiring of BioTissue’s direct sales representatives and the assumption of sales agent and consulting agreements with independent sales agents. We also assumed agreements with GPO and Integrated Delivery Networks ("IDN") which facilitate procurement and distribution of our products to affiliated hospitals, providers and healthcare facilities. As part of the BioTissue acquisition, we also licensed all patents related to the manufacture and commercialization of the Neox® and Clarix® product lines, including the CryoTek®, and SteriTek® technologies, as well as certain related trademarks. BioTissue retained ownership of the Licensed Intellectual Property which it utilizes in the manufacture and commercialization of its other products. The aggregate purchase consideration of the asset acquisition consisted of an upfront cash payment of approximately (i) $15,000,000, and (ii) the Clearance Payment of up to $10,000,000.

Read the full filing description · filed 14 Aug 2026

At a glance

Sector

Healthcare

Industry

Biological Products, (No Diagnostic Substances)